New drug cocktail shows promise for tough lung cancer cases
NCT ID NCT06029127
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a new drug called gimistotug (BGB-A445) combined with either another experimental drug (BGB-15025) or the standard chemo docetaxel in 35 people with advanced non-small cell lung cancer. All participants had already tried an immunotherapy and chemotherapy. The main goal was to see if the combinations could shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gimistotug (BGB-A445) plus BGB-15025 or docetaxel
What this could lead to
If successful, this could point toward a new combination treatment option for people with non-small cell lung cancer whose disease has progressed after standard therapy.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Jiangnan University South Campus
Wuxi, Jiangsu, 214122, China
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Daping Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, 400042, China
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
-
Gansu Provincial Hospital
Lanzhou, Gansu, 730000, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, Seoul Teugbyeolsi, 03722, South Korea
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
-
The Catholic University of Korea, St Vincents Hospital
Suwon, Gyeonggi-do, 16247, South Korea
-
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Guangzhou, Guangdong, 510405, China
-
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, 330006, China
-
The Second Affiliated Hospital of Shandong First Medical University
Taian, Shandong, 271099, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
Weihai Municipal Hospital
Weihai, Shandong, 264299, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China